Methotrexate Accord Healthcare (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate. This limits the synthesis of nucleotides needed for DNA and RNA formation, thereby reducing the replication of rapidly dividing cells such as cancer cells and activated immune cells.

The specific dose of methotrexate is determined by the prescribing clinician based on the patient’s condition, weight, renal function and treatment goals. Dosage regimens can vary widely, ranging from low weekly doses for autoimmune disease to higher, more frequent doses in oncology protocols.

Methotrexate is classified as teratogenic and is contraindicated in pregnancy because it can cause fetal malformations and miscarriage. It is also excreted in breast milk, so breastfeeding is not recommended while receiving the drug. Women of child‑bearing potential should use effective contraception during treatment and for a defined period after discontinuation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Methotrexate is often considered the first‑line disease‑modifying antirheumatic drug (DMARD) because of its proven efficacy and cost‑effectiveness. Alternatives such as leflunomide or biologic agents (e.g., TNF inhibitors) may be used when methotrexate is insufficient or not tolerated, but they are generally more expensive and may have different safety profiles.

Methotrexate Accord Healthcare should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly sealed to maintain stability.

The product is supplied as a sterile injectable solution and can be given by intra‑arterial, intramuscular, or intravenous injection, depending on the clinical indication and prescribing guidance. Administration is performed by qualified healthcare professionals in a controlled setting.

The most critical risks include severe liver toxicity, pulmonary fibrosis, life‑threatening bone marrow suppression, and acute renal failure. Patients should be monitored regularly for signs of organ dysfunction, and any unexpected symptoms such as persistent cough, jaundice, or unexplained bruising should prompt immediate medical evaluation.

Methotrexate is contraindicated in patients with known hypersensitivity to the drug, active severe liver disease, significant renal impairment, uncontrolled infections, and in women who are pregnant or planning to become pregnant. Caution is also advised for individuals with pre‑existing blood dyscrasias or pulmonary disease.